Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

NCT02846792 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Immunotherapy approved for NSCLC in the first line setting

Conditions

ALK Gene Translocation
EGFR Activating Mutation
Recurrent Non-Small Cell Lung Carcinoma
ROS1 Gene Translocation
Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Stage IV Non-Small Cell Lung Cancer AJCC v7

Interventions

BIOLOGICAL: Nivolumab
DRUG: Plinabulin

Sponsor

University of Washington

Collaborators

[object Object]